|
|
|
|
|
|
|
28.02.26 - 04:21
|
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (PR Newswire)
|
|
|
NEW YORK and NEW ORLEANS, Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a......
|
|
|
28.02.26 - 04:09
|
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)
|
|
|
NEW YORK and NEW ORLEANS, Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.02.26 - 00:06
|
The Baldwin Group Announces Future Leadership Transition in its Underwriting, Capacity, and Technology Solutions Segment (Business Wire)
|
|
|
Amy Carlisle to be named CEO; Jim Roche to become Executive ChairmanTAMPA, Fla.--(BUSINESS WIRE)--The Baldwin Group (“Baldwin” or the “Company”) (NASDAQ: BWIN), a leading independent insurance brokerage and advisory firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced a long-planned leadership transition within its Underwriting, Capacity, & Technology Solutions (“UCTS”) operating group, effective January 1, 2027. Amy Carlisle will become Chief Executive Officer of UCTS, succeeding Jim Roche, who will assume the role of Executive Chairman, UCTS for a period of three years. The transition reflects a deliberate, multi-year succession plan designed to ensure continuity and support the long-term strength and performance of the UCTS business.
As CEO, UCTS, Ms. Carlisle will oversee the segment's MGA and wholesale businesses, capacity operations, and finance and accounting functions. She will report to Chief Executive Officer, Trevor Baldwi...
|
|
|
28.02.26 - 00:00
|
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older (GlobeNewswire EN)
|
|
|
COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic exposure to CNP over the weekly dosing interval. Continued approval for this indication, which was based on an improvement in annualized growth velocity (AGV), may be contingent upon verification and description of clinical benefit in confirmatory trial(s)....
|
|
|
|
|
|
|
|
|
27.02.26 - 23:03
|
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025 (Business Wire)
|
|
|
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025.
Financial Results
Revenue
Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024.
Net (Loss) Income
The Company reported a net loss of $2.4 million in fiscal 2025 or $0.30 per basic and diluted share, compared to net income of $402,000 in fiscal 2024 or $0.05 per basic and diluted share. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $...
|
|
|
|
|
27.02.26 - 22:33
|
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company's American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision....
|
|
|
27.02.26 - 22:21
|
Prothena Announces up to $100 Million Share Repurchase Plan (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding ordinary shares, par value $0.01 per share.
Prothena had cash, cash equivalents and restricted cash of $308.4 million and no debt as of December 31, 2025. Excluding any potential purchases under this Share Repurchase Plan, Prothena expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerativ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
